Inotuzumab ozogamicin for the treatment of acute lymphoblastic leukemia

Therapy for adult acute lymphoblastic leukemia (ALL) with multiagent cytotoxic chemotherapy has not been as successful as that for pediatric patients. The advent of targeted monoclonal antibodies against common cell surface antigens (i.e. CD19, CD20, and CD22) has resulted in improved outcomes witho...

Descripción completa

Detalles Bibliográficos
Autores principales: Savoy, J. Michael, Welch, Mary Alma, Nasnas, Patrice E., Kantarjian, Hagop, Jabbour, Elias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7992772/
https://www.ncbi.nlm.nih.gov/pubmed/33815734
http://dx.doi.org/10.1177/2040620718812013
_version_ 1783669448395194368
author Savoy, J. Michael
Welch, Mary Alma
Nasnas, Patrice E.
Kantarjian, Hagop
Jabbour, Elias
author_facet Savoy, J. Michael
Welch, Mary Alma
Nasnas, Patrice E.
Kantarjian, Hagop
Jabbour, Elias
author_sort Savoy, J. Michael
collection PubMed
description Therapy for adult acute lymphoblastic leukemia (ALL) with multiagent cytotoxic chemotherapy has not been as successful as that for pediatric patients. The advent of targeted monoclonal antibodies against common cell surface antigens (i.e. CD19, CD20, and CD22) has resulted in improved outcomes without additional toxicities. Inotuzumab ozogamicin is an anti-CD22 antibody–drug conjugate approved for the treatment of relapsed or refractory B-cell precursor ALL. It improved outcomes compared with standard salvage chemotherapy. Its combination with low-intensity chemotherapy in the relapse setting and in frontline elderly patients is promising.
format Online
Article
Text
id pubmed-7992772
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-79927722021-04-02 Inotuzumab ozogamicin for the treatment of acute lymphoblastic leukemia Savoy, J. Michael Welch, Mary Alma Nasnas, Patrice E. Kantarjian, Hagop Jabbour, Elias Ther Adv Hematol Review Therapy for adult acute lymphoblastic leukemia (ALL) with multiagent cytotoxic chemotherapy has not been as successful as that for pediatric patients. The advent of targeted monoclonal antibodies against common cell surface antigens (i.e. CD19, CD20, and CD22) has resulted in improved outcomes without additional toxicities. Inotuzumab ozogamicin is an anti-CD22 antibody–drug conjugate approved for the treatment of relapsed or refractory B-cell precursor ALL. It improved outcomes compared with standard salvage chemotherapy. Its combination with low-intensity chemotherapy in the relapse setting and in frontline elderly patients is promising. SAGE Publications 2018-11-22 /pmc/articles/PMC7992772/ /pubmed/33815734 http://dx.doi.org/10.1177/2040620718812013 Text en © The Author(s), 2018 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Review
Savoy, J. Michael
Welch, Mary Alma
Nasnas, Patrice E.
Kantarjian, Hagop
Jabbour, Elias
Inotuzumab ozogamicin for the treatment of acute lymphoblastic leukemia
title Inotuzumab ozogamicin for the treatment of acute lymphoblastic leukemia
title_full Inotuzumab ozogamicin for the treatment of acute lymphoblastic leukemia
title_fullStr Inotuzumab ozogamicin for the treatment of acute lymphoblastic leukemia
title_full_unstemmed Inotuzumab ozogamicin for the treatment of acute lymphoblastic leukemia
title_short Inotuzumab ozogamicin for the treatment of acute lymphoblastic leukemia
title_sort inotuzumab ozogamicin for the treatment of acute lymphoblastic leukemia
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7992772/
https://www.ncbi.nlm.nih.gov/pubmed/33815734
http://dx.doi.org/10.1177/2040620718812013
work_keys_str_mv AT savoyjmichael inotuzumabozogamicinforthetreatmentofacutelymphoblasticleukemia
AT welchmaryalma inotuzumabozogamicinforthetreatmentofacutelymphoblasticleukemia
AT nasnaspatricee inotuzumabozogamicinforthetreatmentofacutelymphoblasticleukemia
AT kantarjianhagop inotuzumabozogamicinforthetreatmentofacutelymphoblasticleukemia
AT jabbourelias inotuzumabozogamicinforthetreatmentofacutelymphoblasticleukemia

Ejemplares similares